A randomized double bline phase 3 study of the JAK 1/2 inhibitor Ruxotinib or placebo in conbination with capecitbine in subjects with advanced or metastatic adenocarcinoma of the pancreas
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
September 1, 2014
End Date
April 19, 2017
Administered By
Duke Cancer Institute
Awarded By
Incyte Corporation
Start Date
September 1, 2014
End Date
April 19, 2017